Approximately 50 – 60% of patients with melanoma have BRAF-activating tumors, meaning they are amenable to treatment with combination BRAF/MEK inhibitors. However, immunotherapy is also a highly effective treatment for patients with BRAF-activating tumors. Given the benefit of both types of therapies in the adjuvant setting, there are uncertainties regarding which adjuvant treatment to offer patients with stage III disease. The critical question revolves around which adjuvant treatment strategy provides the best opportunity for sustained recurrence-free survival.Report with a jury of your peers to debate the optimal adjuvant treatment approach for a patient with fully resected, stage III BRAF-mutant melanoma. View the persuasive evidence and listen to expert witnesses defend the pros and cons for this high-risk patient population. Cast your polling vote as the case proceeds. We’ll see you in court to render a verdict in an important case with implications for your clinical practice!Rel